10.13.26 -- Structuring CGT Deals For The Long Term With Troutman Pepper Locke's EA Weeks, J.D., Ph.D.

Achieving consistent Homology Directed Repair (HDR) in iPSCs requires optimized CRISPR design and workflows. See how advanced reagents and targeted enhancement strategies improve insertion efficiency.

mRNA poly(A) tail analysis depends on targeted digestion, clean LC/MS conditions, and reliable deconvolution. Uncover how RNase 4 digestion and optimized ion-pairing methods support reproducible results.

Modern control systems are helping manufacturers improve traceability and streamline compliance. Learn how digital tools are simplifying migration and enabling smarter, more connected operations.

Explore how bone marrow, umbilical cord, and adipose MSCs produce extracellular vesicles with distinct characteristics, and why 3D culture systems consistently outperform 2D platforms in productivity.

How should you approach building your aseptic processing line? Gain insight into the advantages of using a modular, configurable technology rather than custom fill-finish solutions.

Generate GMP-compliant mesenchymal stem cells (MSCs) at scale with a closed, automated workflow. Decode how to optimize MSC harvest yields and ensure trilineage differentiation.

Sequencing techniques play a crucial role in establishing the quality attributes of a variety of therapeutic products. Learn what advantages NGS offers for obtaining accurate sequences.

Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

Pharmaceutical manufacturers need more than raw production data to scale AI. Read how contextualized, governed IT/OT integration can turn disconnected shop-floor signals into real-time decisions.

Efficient cell line development demands reliable clone selection and early removal of candidates. Filtration and sample prep solutions can strengthen sterility, simplify workflows, and support decisions.

Starting material variability risks downstream success. Gain essential insights into cellular characterization to protect therapy production runs.

A robust platform process can help ensure therapeutic efficacy and supply chain security for LVV-based products, as well as support aggressive development and commercialization timelines.

Manual prep creates bottlenecks in genome sequencing. Examine an automated high-input workflow that supports long reads while cutting reagents.

Synthetic DNA replaces plasmids for AAV production, cutting contaminants and variability and improving reproducibility and scalability from research to manufacturing.

Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.